Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 3
2015 1
2016 2
2017 4
2018 6
2019 5
2020 5
2021 9
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Among authors: hescot s. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma.
Roux C, Boileve A, Faron M, Lamartina L, Delpla A, Tselikas L, Durand-Labrunie J, Hescot S, de Baere T, Hadoux J, Deschamps F, Baudin E. Roux C, et al. Among authors: hescot s. Cancers (Basel). 2022 May 31;14(11):2730. doi: 10.3390/cancers14112730. Cancers (Basel). 2022. PMID: 35681708 Free PMC article.
New endpoints in adrenocortical carcinoma studies: a mini review.
Faron M, Lamartina L, Hescot S, Moog S, Deschamps F, Roux C, Libe R, Durand-Labrunie J, Al Ghuzlan A, Hadoux J, Baudin E. Faron M, et al. Among authors: hescot s. Endocrine. 2022 Sep;77(3):419-424. doi: 10.1007/s12020-022-03128-2. Epub 2022 Jul 23. Endocrine. 2022. PMID: 35869971 Review.
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F. Castinetti F, et al. Among authors: hescot s. Ann Endocrinol (Paris). 2018 Oct;79(5):591-595. doi: 10.1016/j.ando.2018.07.005. Epub 2018 Jul 11. Ann Endocrinol (Paris). 2018. PMID: 30056975 Review.
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, Vezzosi D, Do Cao C, Libé R, Le Tourneau C, Baudin E, Massard C, du Rusquec P; from the French ENDOCAN-COMETE network. Hescot S, et al. Eur J Cancer. 2023 Aug;189:112917. doi: 10.1016/j.ejca.2023.05.006. Epub 2023 May 16. Eur J Cancer. 2023. PMID: 37277263 Clinical Trial.
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G, Bièche I, Dupain C, Borcoman E, du Rusquec P, Ricci F, Hescot S, Sablin MP, Tresca P, Bello D, Dubot C, Loirat D, Frelaut M, Lecerf C, Le Tourneau C, Kamal M. Marret G, et al. Among authors: hescot s. JCO Precis Oncol. 2021 Nov;5:215-226. doi: 10.1200/PO.20.00280. JCO Precis Oncol. 2021. PMID: 34994597 Review.
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Hadoux J, Walter T, Kanaan C, Hescot S, Hautefeuille V, Perrier M, Tauveron I, Laboureau S, Do Cao C, Petorin C, Blanchet O, Faron M, Leteurtre E, Rousselet MC, Joubert Zakeyh J, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Lombard-Bohas C, Ducreux M, Scoazec JY, Baudin E; Groupe d’Etude des Tumeurs Endocrines (GTE); ENDOCAN-RENATEN network. Hadoux J, et al. Among authors: hescot s. Endocr Relat Cancer. 2022 Aug 17;29(10):569-580. doi: 10.1530/ERC-22-0102. Print 2022 Oct 1. Endocr Relat Cancer. 2022. PMID: 35920609
Prognostic of recurrence and survival in poorly differentiated thyroid cancer.
Hescot S, Al Ghuzlan A, Henry T, Sheikh-Alard H, Lamartina L, Borget I, Hadoux J, Baudin E, Dupuy C, Nikitski AV, Nikiforov YE, Schlumberger M, Nikiforova MN, Leboulleux S. Hescot S, et al. Endocr Relat Cancer. 2022 Sep 30;29(11):625-634. doi: 10.1530/ERC-22-0151. Print 2022 Nov 1. Endocr Relat Cancer. 2022. PMID: 36040800
Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal.
Moog S, Castinetti F, DoCao C, Amar L, Hadoux J, Lussey-Lepoutre C, Borson-Chazot F, Vezzosi D, Drui D, Laboureau S, Raffin Sanson ML, Lamartina L, Pierre P, Batisse Ligner M, Hescot S, Al Ghuzlan A, Renaudin K, Libé R, Laroche S, Deniziaut G, Gimenez-Roqueplo AP, Jannin A, Leboulleux S, Guerin C, Faron M, Baudin E. Moog S, et al. Among authors: hescot s. J Clin Endocrinol Metab. 2021 Aug 18;106(9):2726-2737. doi: 10.1210/clinem/dgab202. J Clin Endocrinol Metab. 2021. PMID: 33782697
Dyslipidemia causes overestimation of plasma mitotane measurements.
Paci A, Hescot S, Seck A, Jublanc C, Mercier L, Vezzosi D, Drui D, Quinkler M, Fassnacht M, Bruckert E, Lombès M, Leboulleux S, Broutin S, Baudin E. Paci A, et al. Among authors: hescot s. Endocrinol Diabetes Metab Case Rep. 2016;2016:150135. doi: 10.1530/EDM-15-0135. Epub 2016 Jun 10. Endocrinol Diabetes Metab Case Rep. 2016. PMID: 27298727 Free PMC article.
44 results